Anny Setijo Rahaju, Anny and Arifa Mustika, Arifa and Priangga Adi Wiratama, Priangga and Leonita Agustina Hambalie, Leonita and Novalia Guntarno, Novalia and Lukman Hakim, Lukman and Doddy M. Soebadi, Doddy Correlation Between VEGF and EGFR Expression in Urothelial Carcinoma of Bladder. Journal of International Dental and Medical Research, 14 (2). ISSN 1309-100X

	Text (Artikel) 9 ARTIKEL.pdf Download (3MB)
	Text (Laik Etik) 9 etik.pdf Download (174kB)
	Text (Turnitin) 9 turnitin.pdf Download (2MB)
	Text (Kualitas Karil & Kesesuaian Bidang Ilmu) Karil (1)-9.pdf Download (113kB)
	Text (Bukti Korespondensi) Bukti Koresponden C.9.pdf Download (376kB)

Abstract

Abstract Bladder cancer is the ninth malignancy of the genitourinary system in the world. Urothelial cell carcinoma is the commonest histological type. There are no good therapeutic options to date. Vascular endothelial growth factor (VEGF) is a growth factor that is essential to stimulate angiogenesis. Tumor growth relies on angiogenesis and determines the therapy. The epidermal growth factor receptor (EGFR) is known as a tyrosine kinase transmembrane receptor. EGFR is involved in the regulation of VEGF. Several researches have shown that EGFR stimulation induces VEGF expression. Therefore, this research was conducted to analyze the relationship between VEGF and EGFR, as the basis of therapy using anti-VEGF and anti-EGFR. An observational research was conducted on 53 formalin fixed paraffin-embedded tissue from Radical Cystectomy patients urothelial carcinoma of bladder which was at Dr. Soetomo General Academic Hospital Surabaya, Indonesia during 2010 - 2019. Immunohistochemistry was conducted using VEGF and EGFR antibodies. Significant positive correlation was seen between EGFR and VEGF expression in bladder urothelial carcinoma. VEGF and EGFR expression can use as the basis of therapy using anti-VEGF and anti-EGFR in bladder urothelial carcinoma.

Actions (login required)

View Item